The expanding therapeutic armamentarium for inflammatory bowel disease: How to choose the right drug[s] for our patients?

Pieter Hindryckx, Pieter Hindryckx, Niels Vande Casteele, Niels Vande Casteele, Gregor Novak, Gregor Novak, Reena Khanna, Reena Khanna, Geert D'Haens, Geert D'Haens, William J. Sandborn, William J. Sandborn, Silvio Danese, Vipul Jairath, Vipul Jairath, Vipul Jairath, Brian G. Feagana, Brian G. Feagana

Research output: Contribution to journal › Review article

Abstract

© 2017 European Crohn's and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. The therapeutic landscape for inflammatory bowel disease [IBD] is rapidly evolving. Two new biologic drugs, vedolizumab and ustekinumab, have recently entered the marketplace, the first biosimilars have been introduced, and several other agents are at an advanced stage of clinical development. In parallel, therapeutic goals have shifted from symptom control towards mucosal healing and prevention of bowel damage. In the coming years, gastroenterologists will be faced with unprecedented choices when selecting the best treatment for their patients with IBD. In this article, we review existing data on the mechanisms of action, efficacy, and safety of recently approved and late-stage pipeline therapies, and use this information to speculate on the positioning of these drugs, alone or in combination, in therapeutic algorithms for Crohn's disease and ulcerative colitis.
Original languageEnglish
Pages (from-to)105-109
Number of pages5
JournalJournal of Crohn's and Colitis
Volume12
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Keywords

  • IL-23 antagonists
  • Inflammatory bowel disease
  • JAK inhibitors
  • Pipeline
  • Smad7
  • Sphingosine-1 phosphate
  • Therapy
  • TNF antagonists

Access to Document

Fingerprint Dive into the research topics of 'The expanding therapeutic armamentarium for inflammatory bowel disease: How to choose the right drug[s] for our patients?'. Together they form a unique fingerprint.

    • Cite this

    Hindryckx, P., Hindryckx, P., Casteele, N. V., Casteele, N. V., Novak, G., Novak, G., Khanna, R., Khanna, R., D'Haens, G., D'Haens, G., Sandborn, W. J., Sandborn, W. J., Danese, S., Jairath, V., Jairath, V., Jairath, V., Feagana, B. G., & Feagana, B. G. (2018). The expanding therapeutic armamentarium for inflammatory bowel disease: How to choose the right drug[s] for our patients? Journal of Crohn's and Colitis, 12(1), 105-109. https://doi.org/10.1093/ecco-jcc/jjx117